biotech

Allevi Author: NJIT Bioprints Vascularized Tissue

NJIT allevi guvendiren vascular vasculature vein 3d bioprint bioprinted bioprinter

We are VERY excited to announce the latest addition the Allevi Author Club; the Guvendiren Lab from the New Jersey Institute of Technology.

Dr. Guvendiren’s lab focuses on creating novel bioinks for tissue engineering and regenerative medicine applications with a focus on 3D bioprinting. Their most recent paper, published in Acta Biomaterialia and titled “3D bioprinting of complex channels within cell-laden hydrogels”, explores their new approach to 3D bioprinting vasculature into 3D tissue.

There are many different methods for creating microchannels within constructs, including electrospinning, fiber bonding, and casting solvents into molds. However these techniques don’t allow for precise control of channel size, shape or location. They can also be time-consuming and restrictive in the number of cell lines that you are able to work with simultaneously.

The Guvendiren lab is exploring a new approach to creating these channel-laden tissues using their Allevi 2 bioprinter. In their paper, they explore a method of 3D bioprinting sacrificial bioinks into cell-laden hydrogels (pluronic into methacrylated alginate/methacrylated hyaluronic acid to be specific). This technique allows them to create custom channel geometries, control channel thickness and tune the hydrogel rigidity. They also explored a super cool technique wherein they alter the printhead speed in order to create channels of differing diameters.

Their images from confocal scanning show strong endothelial cell (HUVEC) attachment to the channel walls and depict the final 3D bioprinted vein construct.

HUVEC vascular channel vein 3d bioprinted bioprint allevi NJIT guvendiren

This research explores important techniques for creating tunable microchannels within 3D tissues. We can imagine a future wherein these methods are used to create 3D bioprinted organs with custom and complex vascular networks. It could also be used to create custom 3D models to study disease progression and test drug efficacy and toxicity. Amazing work, Guvendiren Lab!!

Click through to read their material characterization and learn more about their bioprinting approach: https://www.sciencedirect.com/science/article/pii/S1742706119301515.

Allevi Named Fierce15 Class of 2018!

fierce+biotech+award.jpg

We are so honored to be selected by FierceMedTech as one of their Fierce 15 MedTech Companies of 2018!

What really makes Allevi fierce is our amazing community of users who are using their Allevi bioprinters to revolutionize the way we model disease, test novel drugs, and study the body outside the body.

We're proud to empower Allevi users with the tools that will make tangible impacts on patients' lives. Together, we can change the future of medicine. Thank you, FierceMedTech, for your recognition!

You can read more here.

Bioprinting in the News: 'Bioprinters Are Churning Out Living Fixes to Broken Spines' By WIRED

Image courtesy of www.wired.com

Image courtesy of www.wired.com

Bioprinters are an essential piece of lab equipment for any scientist, researcher, or doctor that wants to study cells in a relevant way. This is because cells in 3D behave differently than their counterparts studied in a 2D environment; they express more accurate biomarkers and perform more physiologically relevant actions. Bioprinters accelerate the pace of research and allow scientists to find innovative solutions to real world problems.

This awesome article by WIRED profiles a team at UC San Diego that has bioprinted a section of spinal cord that can be custom-fit into a patient’s injury.

It’s awesome to see how bioprinting allows researchers to reliably study the body outside the body. Together, we can change the way we study and treat illness!

Read the full article here.

Allevi Joins Johnson&Johnson's JPOD Philadelphia Community

As new applications continue to be developed within the Allevi community, we feel the responsibility to join larger ecosystems that connect us with more engineers, scientists, and physicians that can benefit from the power of Allevi’s solutions. Our first successful relationship with a broader ecosystem has been with VWR. They continue to help us introduce our platform to accelerate science around the world. Adding geometry to biology is becoming a standard to be able to generate accurate representations of the body outside the body. 

At Allevi, we are now ready to begin to understand how to translate our communities’ scientific discoveries into the breakthroughs of tomorrow. To do this we realize that we need to co-create solutions with those at the front lines who are bringing new drugs to market, fighting diseases at the bedside, and producing novel solutions for the healthcare system.

Therefore, we are excited to join the Johnson & Johnson Innovation, JLABS JPOD @ Philadelphia community. We believe access to this ecosystem helps us connect with those who understand how Allevi’s applications can serve the healthcare industry. These interactions will guide our community today and in the future. Together we can target healthcare’s biggest needs by creating more accurate, predictable 3D biology models.

As we continue to collaborate with the Johnson & Johnson Innovation community, we will look forward to receiving mentorship, brainstorming with great minds in the industry, and continuing to grow Allevi. It takes a village to raise a company and we are happy to have the JLABS village help us reach new heights.

Dr. Robert Langer Joins the A-Team

Dr robert Langer scientific advisor to Allevi 3d bioprinters.jpg

At Allevi, we believe that the democratization of bioprinting can help millions lead longer and healthier lives. By empowering scientist to make complex, relevant, personalized 3D tissues so many breakthroughs will be achieved within healthcare and humanity. And we are at the heart of catalyzing this change.

We have already seen so much success from our users bringing to life new ideas. They have shown us how patterning cells and biomaterials in new ways can generate scientific results unseen before. For example, Dr. Binatta Joddar from the University of El Paso Texas published how the difference between lattice and rectangular sheet structures matter for cardiac tissue engineering. On that same note, Dr. Parr and Dr. McAlpine from The University of Minnesota published how the specific placement of iPS neuron cells in relation to supporting cells matters to achieve relevant spinal cord tissue engineering. And these are just a few examples out of the multitude of papers being created by Allevi products.

As Allevi’s publication list grows, we are excited to begin to understand how we can translate these relevant scientific results into impactful products for the benefit of patients. However, we understand that to help millions in the future we have to continue learn from those who have helped millions in the past.

Therefore, we are excited to announce Dr. Robert Langer has joined our Scientific Advisory Board to teach us the fundamentals of how he has translated so many breakthroughs to patients and created new industries. Dr. Langer a Professor at MIT, has helped start several biotechnology companies, has licensed or sub-licensed over 350 patents to different companies and runs one of the largest bioengineering research labs in the world. “I’m delighted to be working with Allevi and their excellent team,” stated Dr. Langer.

We will work closely with Dr. Robert Langer as well as our other amazing advisors, Dr. Anthony Atala, Dr. Yu Shrike Zhang, and Dr. Aleksander Skardal to understand the best way to translate breakthroughs in our bioprinting community to begin to directly help patients at the bedside.